

Oxcarbazepine Metabolite, Serum

# **Overview**

#### **Useful For**

Monitoring serum concentration during oxcarbazepine therapy

Assessing compliance

Assessing potential toxicity

#### **Method Name**

High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)

#### **NY State Available**

Yes

# **Specimen**

# **Specimen Type**

Serum Red

## Specimen Required

Supplies: Sarstedt Aliquot Tube 5 mL (T914)

**Collection Container/Tube:** Red top (serum gel/SST is **not acceptable**)

Submission Container/Tube: Plastic vial

**Specimen Volume:** 1 mL **Collection Instructions:** 

- 1. Collect specimen immediately before next scheduled dose.
- 2. Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.

#### **Forms**

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

- -Neurology Specialty Testing Client Test Request (T732)
- -<u>Therapeutics Test Request</u> (T831)

# Specimen Minimum Volume

0.5 mL

# **Reject Due To**

Gross	ОК
hemolysis	
Gross lipemia	OK



Oxcarbazepine Metabolite, Serum

Gross icterus	ОК

### **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum Red	Refrigerated (preferred)	28 days	
	Ambient	28 days	
	Frozen	28 days	

# **Clinical & Interpretive**

#### **Clinical Information**

Oxcarbazepine (OCBZ) is approved as monotherapy and adjunctive therapy for partial seizures with and without secondary generalized seizures in adults and as adjunctive therapy for partial seizures in children. In humans, OCBZ is a prodrug that is almost immediately and completely metabolized to 10-hydroxy-10,11-dihydrocarbamazepine, known as monohydroxy carbamazepine (MHC), an active metabolite that is responsible for OCBZ's therapeutic effect. The elimination half-life is approximately 2 hours for OCBZ and 7 to 11 hours for MHC. The therapeutic range (10-35 mcg/mL) is based on concentrations of the metabolite, not the parent drug; this assay measures the metabolite only.

In clinical practice, the OCBZ dosage should be individually adjusted for each patient to achieve the desired therapeutic response. Toxicity associated with OCBZ includes hyponatremia, dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, and abnormal gait. These toxicities may be observed when blood concentrations are in the therapeutic range.

#### Reference Values

Oxcarbazepine metabolite: 10-35 mcg/mL

#### Interpretation

Therapeutic ranges are based on specimens collected at trough (ie, immediately before the next dose). Most individuals display optimal response to oxcarbazepine therapy when serum levels of the metabolite (measured in this assay) are between 10 and 35 mcg/mL. Some individuals may respond well outside of this range or may display toxicity within the therapeutic range. Thus, interpretation should include clinical evaluation.

#### **Cautions**

Toxic levels have not been well established.

This test cannot be performed on whole blood. Serum must be separated from cells within 2 hours of collection.

#### **Clinical Reference**

- 1. Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62
- 2. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol. 2001;15(6):405-417
- 3. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994;35(Suppl



Oxcarbazepine Metabolite, Serum

3):S10-S13

- 4. Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res. 2000;31(2):202-205
- 5. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45(11):1061-1075
- 6. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276

#### **Performance**

# **Method Description**

The serum sample is diluted in acetonitrile containing internal standard. The protein precipitate is centrifuged, and a portion of the supernatant is diluted with mobile phase for detection by a tandem mass spectrophotometer. (Unpublished Mayo method)

# **PDF Report**

No

# Day(s) Performed

Monday through Saturday

#### Report Available

1 to 3 days

#### **Specimen Retention Time**

14 days

## **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Superior Drive

# **Fees & Codes**

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

#### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.



Oxcarbazepine Metabolite, Serum

# **CPT Code Information**

80183

# **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
ОМНС	Oxcarbazepine Metabolite (MHC), S	31019-3

Result ID	Test Result Name	Result LOINC® Value
81030	Oxcarbazepine Metabolite (MHC), S	31019-3